Table 2.
Breast cancer subtype | Primary treatment | Before COVID-19 | During COVID-19 | P value |
---|---|---|---|---|
T1cN0 triple negative | Chemotherapy | 227 (60.2%) | 186 (49.3%) | 0.002 |
Surgery | 150 (39.8%) | 191 (50.7%) | ||
ER negative HER2 positive pT1c | Chemotherapy in combination with anti HER2 therapy | 250 (66.3%) | 218 (57.8%) | 0.016 |
Surgery | 126 (33.7%) | 159 (42.2%) |